fda tirzepatide announcement With growing uncertainty surrounding government funded healthcare programs, this comes as a welcome surprise and a move that could benefit many people. Recent announcements surrounding the Medicare #GLP1 Bridge program have drawn No, the FDA is not

However, anyone with cardiovascular concerns should work with a physician and monitor blood pressure regularly throughout

Expanding Injury Claims Beyond gastroparesis and vision loss, researchers continue documenting additional adverse effects associated with Ozempic and other GLP-1 drugs

In contrast, some patients in these trials showed improvements in inflammation-related conditions

Endocrine and metabolic shifts GLP-1 medications also change insulin dynamics, influence thyroid behavior, and act on metabolic hormones

It is not approved by the FDA, EMA, or any regulatory authority for human use, diagnosis, treatment, or supplementation